Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
Completed
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Phase 1
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable
safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977
that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care
prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time
[TEG-R]) will be identified.
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
Completed
Perosphere, Inc.
Phase 1
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable
safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977
that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care
prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time
[TEG-R]) will be identified.
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Completed
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Phase 2
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and
safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban
measuring clotting times using Whole Blood Clotting Time (WBCT).
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Completed
Perosphere, Inc.
Phase 2
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and
safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban
measuring clotting times using Whole Blood Clotting Time (WBCT).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
